Non-Viral Drug Delivery Systems Market Expected to Show Steady Growth, Approaching $19.07 Billion by 2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Non-Viral Drug Delivery Systems Market By 2030 Starting From Its 2026 Size?
The non-viral drug delivery systems market has seen considerable growth recently. Its value is anticipated to rise from $9.84 billion in 2025 to $11.26 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.4%. This historical expansion can be linked to factors including reliance on viral delivery methods, limited awareness of non-viral techniques, emerging biologics development, initial regulatory frameworks for drug delivery, and early academic research focus on nanoparticles.
The non-viral drug delivery systems market is anticipated to experience significant expansion in the coming years. It is projected to attain a value of $19.07 billion by 2030, reflecting a compound annual growth rate (CAGR) of 14.1%. The growth during this forecast period primarily stems from developments in polymer-based carriers, the increasing prevalence of RNA and DNA therapeutics, augmented investment in personalized medicine, the widening scope of contract development and manufacturing organizations (CDMOs), and a rise in collaborations between pharmaceutical entities and academic institutions. Key trends expected in the forecast period involve a growing adoption of non-viral delivery platforms for targeted therapies, an increased utilization of nanoparticles and liposome-based carriers, a heightened focus on mitigating immune responses and enhancing safety, the progression of personalized medicine and targeted therapeutics, and the expansion of CDMOs and academic research partnerships.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
Which Market Drivers Are Supporting The Expansion Of The Non-Viral Drug Delivery Systems Market?
The escalating demand for personalized medicines is expected to propel the growth of the non-viral drug delivery systems market going forward. Personalized medicine is a medical approach that customizes treatment based on an individual’s genetic makeup, lifestyle, and environment. The demand for personalized medicine is rising as it leads to more effective treatments by targeting the specific causes of disease in each patient. Non-viral systems assist personalized medicine by safely delivering drugs or genes to cells, thereby reducing risks and improving treatment precision. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, representing an increase from 6 approvals in 2022. Therefore, the increasing demand for personalized medicines is driving the growth of the non-viral drug delivery systems market.
Which Segment Categories Define The Non-Viral Drug Delivery Systems Market?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
What Major Market Trends Are Driving Changes In The Non-Viral Drug Delivery Systems Market?
Leading companies active in the non-viral drug delivery system market are concentrating on advanced technologies, such as pre-optimized ionizable lipid mix systems, to enhance the efficiency of developing and delivering RNA-based therapeutics. A pre-optimized ionizable lipid mix system is a formulation technique that allows for the effective encapsulation of RNA molecules into lipid nanoparticles, ensuring robust stability, protection of the payload, and targeted delivery for applications involving gene-based drugs. For example, in September 2024, Cytiva, a US-based biotechnology company, introduced an RNA delivery LNP kit designed to work with its NanoAssemblr Ignite and Ignite+ platforms. This system comes with a ready-to-use ionizable lipid mix, which enables fast screening of RNA payloads and reliable delivery validation, particularly crucial for the development of infectious disease vaccines. It integrates effortlessly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and offers protocols alongside proof-of-concept data to guide users from the initial stages of discovery to clinical evaluation.
Who Are The Top Companies Competing In The Non-Viral Drug Delivery Systems Market?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
Read the full non-viral drug delivery systems market report here:
How Is The Non-Viral Drug Delivery Systems Market Distributed Across Key Geographic Regions?
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Viral Drug Delivery Systems Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24628&type=smp
Browse Through More Reports Similar to the Global Non-Viral Drug Delivery Systems Market 2026, By The Business Research Company
Advanced Drug Delivery Systems Market Report 2026
Electronic Drug Delivery Systems Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
